Screening for hemochromatosis: recommendation statement
- PMID: 16880462
- DOI: 10.7326/0003-4819-145-3-200608010-00008
Screening for hemochromatosis: recommendation statement
Abstract
This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hemochromatosis and the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and on the USPSTF Web site (http://www.preventiveservices.ahrq.gov). The USPSTF is redesigning its recommendation statement in response to feedback from primary care clinicians. The USPSTF plans to release, later in 2006, a new, updated recommendation statement that is easier to read and incorporates advances in USPSTF methods. The recommendation statement in this paper is an interim version that combines existing language and elements with a new format. Although the definitions of grades remain the same, other elements have been revised.
Comment in
-
Summaries for patients. Screening for hemochromatosis: recommendations from the U.S. Preventive Services Task Force.Ann Intern Med. 2006 Aug 1;145(3):I18. doi: 10.7326/0003-4819-145-3-200608010-00002. Ann Intern Med. 2006. PMID: 16880456 No abstract available.
Similar articles
-
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2007 Mar 6;146(5):361-4. Ann Intern Med. 2007. PMID: 17339621
-
Summaries for patients. Screening for hemochromatosis: recommendations from the U.S. Preventive Services Task Force.Ann Intern Med. 2006 Aug 1;145(3):I18. doi: 10.7326/0003-4819-145-3-200608010-00002. Ann Intern Med. 2006. PMID: 16880456 No abstract available.
-
Screening for family and intimate partner violence: recommendation statement.Ann Intern Med. 2004 Mar 2;140(5):382-6. doi: 10.7326/0003-4819-140-5-200403020-00014. Ann Intern Med. 2004. PMID: 14996680
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.Ann Intern Med. 2005 Sep 6;143(5):355-61. doi: 10.7326/0003-4819-143-5-200509060-00011. Ann Intern Med. 2005. PMID: 16144894 Review.
-
Screening for hemochromatosis. A public health perspective.Am J Prev Med. 1999 Feb;16(2):134-40. doi: 10.1016/s0749-3797(98)00141-x. Am J Prev Med. 1999. PMID: 10343890 Review.
Cited by
-
Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.J Clin Invest. 2011 Dec;121(12):4880-8. doi: 10.1172/JCI57693. J Clin Invest. 2011. PMID: 22045566 Free PMC article.
-
Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening.Genes (Basel). 2022 Sep 9;13(9):1622. doi: 10.3390/genes13091622. Genes (Basel). 2022. PMID: 36140790 Free PMC article. Review.
-
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.Blood. 2008 Feb 15;111(4):1848-54. doi: 10.1182/blood-2007-07-099317. Epub 2007 Dec 13. Blood. 2008. PMID: 18079362 Free PMC article. Clinical Trial.
-
Enabling Diagnostic Resulting as a New Category of Secondary Genomic Findings.J Pers Med. 2022 Jan 26;12(2):158. doi: 10.3390/jpm12020158. J Pers Med. 2022. PMID: 35207647 Free PMC article.
-
Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists.Genet Med. 2017 Jan;19(1):112-120. doi: 10.1038/gim.2016.73. Epub 2016 Jun 30. Genet Med. 2017. PMID: 27362912 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical